REFERENCES
1. Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals 2021;14(9):928.
2. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England Journal of Medicine 2015;373(3):220-231.
3. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E. VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. New england journal of medicine 2018;379(17):1612-1620.
4. Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, Hebestreit A, Schenk T, Schindler C, Posselt H-G. Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC pulmonary medicine 2014;14(1):26.
5. Pérez M, Groeneveld IF, Santana‐Sosa E, Fiuza‐Luces C, Gonzalez‐Saiz L, Villa‐Asensi JR, López‐Mojares LM, Rubio M, Lucia A. Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis. Pediatric pulmonology 2014;49(7):641-649.
6. Hebestreit H, Hulzebos EH, Schneiderman JE, Karila C, Boas SR, Kriemler S, Dwyer T, Sahlberg M, Urquhart DS, Lands LC. Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis. American journal of respiratory and critical care medicine 2018(ja).
7. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. American Journal of Respiratory and Critical Care Medicine 2021;203(12):1522-1532.
8. Causer AJ, Shute JK, Cummings MH, Shepherd AI, Bright V, Connett G, Allenby MI, Carroll MP, Daniels T, Saynor ZL. Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of VO2max in people with cystic fibrosis: a retrospective analysis. Journal of Applied Physiology 2018;125(4):1277-1283.
9. Saynor ZL, Barker AR, Oades PJ, Williams CA. A protocol to determine valid V˙ O2max in young cystic fibrosis patients. Journal of science and medicine in sport 2013;16(6):539-544.
10. Saynor ZL, Barker AR, Oades PJ, Williams CA. Reproducibility of maximal cardiopulmonary exercise testing for young cystic fibrosis patients. Journal of Cystic Fibrosis 2013;12(6):644-650.
11. Hildebrand M, VT VH, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist-and hip-worn monitors. Medicine and science in sports and exercise 2014;46(9):1816-1824.
12. Savi D, Schiavetto S, Simmonds NJ, Righelli D, Palange P. Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis. Journal of Cystic Fibrosis 2019;18(3):420-424.
13. Saynor ZL, Barker AR, Oades PJ, Williams CA. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. Pediatric Physical Therapy 2014;26(4):454-461.
14. Lamhonwah AM, Bear, C.E., Huan, L.J., Chiaw, P.K., Ackerley, C.A. and Tein, I. Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise. Annals of neurology 2010;67(6):802-808.
15. Valdivieso AG, Santa-Coloma TA. CFTR activity and mitochondrial function. Redox biology 2013;1(1):190-202.
16. Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, Tierney A, Heritier S, Kotsimbos T, Wilson J. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clinical Science 2017;131(15):2037-2045.
Table 1. Clinical and physical activity characteristics of the cases before and after 6 weeks treatment with Elexacaftor-Tezacaftor-Ivacaftor.
Figure 1. Measurements of exercise capacity before and after 6 weeks treatment with Elexacaftor-Tezacaftor-Ivacaftor. AT, anaerobic threshold;\(\dot{V}\)O2, pulmonary oxygen uptake.